Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297380 | 0.77 | TAAR1 (0.50) | IDO1LOXL2TAAR1AGXTMAOB | |
| SCHEMBL20745628 | 0.77 | IDO1 (0.52) | IDO1LOXL2TAAR1AGXTPLA2G1B | |
| SCHEMBL3304004 | 0.76 | IDO1 (0.41) | IDO1TAAR1AGXT | |
| SCHEMBL1980351 | 0.74 | CYP2A6 (0.47) | IDO1TAAR1 | |
| SCHEMBL2217320 | 0.72 | IDO1 (0.48) | IDO1LOXL2TAAR1AGXTPLA2G1B | |
| SCHEMBL852178 | 0.72 | IDO1 (0.48) | IDO1LOXL2TAAR1AGXTPLA2G1B | |
| SCHEMBL4176273 | 0.72 | CYP3A4 (0.42) | IDO1 | |
| SCHEMBL1444597 | 0.72 | IDO1 (0.48) | IDO1TAAR1AGXTMAOBLMNA | |
| SCHEMBL4924208 | 0.72 | IDO1 (0.48) | IDO1TAAR1AGXTLMNACHRM2 | |
| SCHEMBL158407 | 0.72 | TP53 (0.46) | IDO1TAAR1LMNATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353856-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | NORWEGIAN UNIV SCI & TECH NTNU (NO) | 2025-11-20 | — | — | US | disclosed |
| EP-4578856-A1 | HETEROCYCLIC COMPOUND | Ubience Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024079342-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024071371-A1 | HETEROCYCLIC COMPOUND | ユビエンス株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3500570-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20210214355-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10836764-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190225612-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
| US-5580989-A | Process for the preparation of N-4-[(substituted phenyl)alkylheterocyclic]-N | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0726897-A1 | PROCESS FOR THE PREPARATION OF N-4- (SUBSTITUTED PHENYL)ALKYLTHIENYL]-, AND N-4- (SUBSTITUTED PHENYL)ALKYLFURYL]BUT-3-YN-2-YL]-N-HYDROXYUREA COMPOUNDS | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012589-A1 | PROCESS FOR THE PREPARATION OF N-4-[(SUBSTITUTED PHENYL)ALKYLTHIENYL]-, AND N-4-[(SUBSTITUTED PHENYL)ALKYLFURYL]BUT-3-YN-2-YL]-N-HYDROXYUREA COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225612-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, TPH2 | IDO1 157/4885LOXL2 678/4885TAAR1 55/4885 |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | IDO1 275/4885LOXL2 477/4885TAAR1 76/4885 |
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | IDO1 78/4885LOXL2 2766/4885TAAR1 4395/4885 |
| US-20040067985-A1 | Method of inhibiting angiogenesis | VEGFA, PGF, FLT4 | IDO1 2042/4885LOXL2 660/4885TAAR1 4748/4885 |
| US-20210214355-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, TPH2 | IDO1 219/4885LOXL2 871/4885TAAR1 54/4885 |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR4 | IDO1 3172/4885LOXL2 96/4885TAAR1 397/4885 |
| US-20250353856-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | CSF1R, CSF3R, IL1RN | IDO1 1572/4885LOXL2 3647/4885TAAR1 437/4885 |
| US-10836764-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | IDO1 275/4885LOXL2 477/4885TAAR1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.